BioSpace News Archive

- Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs - - Company to Host Webcast on May 13 at 8:15 a.m. ET -

Talis Biomedical Corporation (“TLIS”), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that the company will be participating in the BofA Securities 2021 Virtual Healthcare Conference. Talis Biomedical’s management is scheduled to participate in the conference on Wednesday, May 12, 2021, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that enrollment has surpassed 50 percent of the total targeted number of randomized trial participants (~n=120) in its double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19

Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has closed the previously announced registered direct offering with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share

A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiated Nomacopan has potential to replace long term steroid treatment (standard of care) in BP, which has multiple adverse effects and increases mortality in this elderly and frail population Recently announced U.S. Food and Drug Administration (FDA) approval of the Investigational New Drug Application (IND)

Led by Nextech Invest and RA Capital Management, with participation from new investors Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital, PFM Health Sciences, and Logos Capital and existing investors Funding will support development of ecDNA directed therapeutic programs and ecDNA companion diagnostic to address oncogene amplified cancers

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 second quarter ended March 31, 2021 and provided its financial outlook for its fiscal 2021.

TRACON Pharmaceuticals announced that it will report its first quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, May 5, 2021.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Japanese Patent Office has decided to grant a patent (No. 2018-542677) for its lead asset, TMB-001,